Pernix Ir. Pain Dac v. Alvogen Malta Operations Ltd.
Decision Date | 08 June 2018 |
Docket Number | Civil Action No. 16–139–WCB |
Citation | 316 F.Supp.3d 816 |
Parties | PERNIX IRELAND PAIN DAC and Pernix Therapeutics, LLC, Plaintiffs, v. ALVOGEN MALTA OPERATIONS LTD., Defendant. |
Court | U.S. District Court — District of Delaware |
Michael P. Kelly, Benjamin A. Smyth, Daniel M. Silver, McCarter & English, LLP, Wilmington, DE, Brendan M. O'Malley, Pro Hac Vice, Christopher P. Borello, Pro Hac Vice, David G. Varghese, Pro Hac Vice, Dominick A. Conde, Pro Hac Vice, Josh Calabro, Pro Hac Vice, for Plaintiffs.
David M. Fry, Jeffrey Thomas Castellano, Nathan Roger Hoeschen, Shaw Keller LLP, Wilmington, DE, Thomas K. Hedemann, Pro Hac Vice, Chad A. Landmon, Pro Hac Vice, Christopher M. Gallo, Pro Hac Vice, Edward M. Mathias, Pro Hac Vice, Matthew J. Becker, Pro Hac Vice, Seth I. Heller, Pro Hac Vice, for Defendants.
In this order, the Court addresses a dispute between the parties over the admissibility of certain exhibits that the plaintiffs (collectively, "Pernix") intend to offer at trial. Defendant Alvogen Malta Operations Ltd. ("Alvogen") contends that the materials are inadmissible as hearsay. Pernix argues that the materials in dispute are non-hearsay and can be used to cross-examine Alvogen's witnesses.
The principal issue before the Court involves the admissibility of five exhibits (PTX 84, 85, 89, 133, and 134) proffered by Pernix. Those exhibits consist of reports by two experts who were retained by a related Alvogen entity in connection with another case. That case, Purdue Pharma L.P. et al. v. Alvogen Pine Brook LLC, Civil Action No. 15–687 ( ), recently settled, quite literally, on the eve of trial. Pernix seeks to use Alvogen's experts' reports to challenge Alvogen's claim that U.S. Patent No. 8,808,740 to Huang is an invalidating prior art reference in this case.
Three of the exhibits in question are reports prepared by Alvogen expert Michael Mayersohn for the Hysingla litigation. To begin with, it is clear that statements by Dr. Mayersohn in those reports may be used to impeach Dr. Mayersohn if he testifies in this case in a manner that is inconsistent with any of the statements he made in the reports he prepared for the Hysingla litigation. That much is not in dispute. See Fed. R. Evid. 613.
What is in dispute is whether the expert reports of Dr. Mayersohn and another of Alvogen's experts, Fernando Muzzio, in the Hysingla litigation are admissible as substantive evidence over a hearsay objection. Pernix's argument is that those statements are non-hearsay statements of an opposing party and are admissible under Fed. R. Evid. 801(d)(2). Alvogen contends that the statements do not satisfy the requirements of any of the categories of party admissions that are covered by that Rule. The Court agrees with Alvogen.1
Rule 801(d) defines certain statements as non-hearsay. The second subsection of that rule, Rule 801(d)(2), lists five types of statements that are attributable to an opposing party and are admissible if offered in evidence against the opposing party. Only three of the five are arguably pertinent here. Rule 801(d)(2)(B) refers to a statement that "is one the party manifested that it adopted or believed to be true." Rule 801(d)(2)(C) refers to a statement that "was made by a person whom the party authorized to make a statement on the subject." And Rule 801(d)(2)(D) refers to a statement that "was made by the party's agent or employee on a matter within the scope of that relationship and while it existed."
There is substantial case law dealing with the admissibility under Rule 801(d)(2) of the testimony, depositions, or reports of an expert against the party that retained the expert. The case law on this subject is mixed, however, with courts reaching different results under a variety of different factual circumstances.
The leading Third Circuit case in this area, Kirk v. Raymark Industries, Inc., 61 F.3d 147 (3d Cir. 1995), held that testimony from a previous, unrelated trial by an expert retained by a party was not admissible under Rule 801(d)(2)(C). The court based its ruling on its analysis of the role of expert witnesses in general. It stated:
Id. at 164 (citations omitted). Although the court in Kirk specifically addressed only Rule 801(d)(2)(C), which deals with statements by a person authorized to make a statement on behalf of a party, the court predicated its ruling on a finding that the expert in that case was not an "agent" of the defendant. In light of that language, Kirk has been interpreted as applying equally to Rule 801(d)(2)(D), which deals with statements by a party's agent on a matter within the scope of the relationship and while it existed.
A number of cases have followed Kirk in applying Rules 801(d)(2)(C) and (D), including several from this district. See, e.g., AVM Techs., LLC v. Intel Corp., Civil Action No. 15-33, 2017 WL 1753999, at *2 (D. Del. May 1, 2017) (); In re Air Crash Near Rio Grande Puerto Rico, Case No. 11–md–02246, 2016 WL 6916599, at *2 (S.D. Fla. Jan. 21, 2016) ( ); Fed. Hous. Fin. Agency v. Nomura Holding Am., Inc., No. 11-cv-6201, 2015 WL 539489, at *10 (S.D.N.Y. Feb. 10, 2015) ( ); N5 Techs. LLC v. Capital One N.A., 56 F.Supp.3d 755, 765 (E.D. Va. 2014) ( ); In re Refco Inc. Sec. Litig., Nos. 07–md–1902 et al., 2013 WL 12191891, at *10 (S.D.N.Y. Mar. 11, 2013) (); SanDisk Corp. v. Kingston Tech. Co., 863 F.Supp.2d 815, 818–19 (W.D. Wis. 2012) ( ); Durham v. County of Maui, 804 F.Supp.2d 1068, 1071 (D. Haw. 2011) (); Lizotte v. Praxair, Inc., 640 F.Supp.2d 1335, 1338–39 (W.D. Wash. 2009) ( ); Pfizer, Inc. v. Ranbaxy Labs., Ltd., No. Civ. A 03-209, 2005 WL 2296613, *1 (D. Del. Sept. 20, 2005) ().2
While, as indicated, there are numerous authorities holding that out-of-court statements in the form of expert testimony, expert depositions, and expert reports are not admissible under Rule 801(d)(2)(C) or (D), there are also many cases holding to the contrary. The leading cases holding that an expert's prior testimony, deposition, or report is admissible as non-hearsay under Rule 801(d)(2)(C) are Collins v. Wayne Corp., 621 F.2d 777 (5th Cir. 1980), and In re Hanford Nuclear Reservation Litigation, 534 F.3d 986 (9th Cir. 2008). In Collins, a products liability action brought against Wayne, a bus manufacturer, following a collision involving one of Wayne's buses, Wayne hired a Mr. Greene as "an expert in the field of automobile collision investigation" to analyze the accident. Mr. Greene was deposed and prepared a report. At trial, the plaintiff wished to use Mr. Greene's deposition testimony and argued it was admissible as a statement of a person authorized by Wayne to make a statement on the subject matter under Rule 801(d)(2)(C). The Fifth Circuit held that Mr. Greene's testimony was admissible on that ground, as Wayne had Collins, 621 F.2d at 782.3
In the Hanford Nuclear...
To continue reading
Request your trial-
Rawers v. United States
...contexts, expert reports and testimony are admissible under rule 801(d)(2). See, e.g., Pernix Ireland Pan Dac v. Alvogen Malta Operations Ltd., 316 F. Supp. 3d 816, 819-22 (D. Del. 2018)(Bryson, J.)(surveying case law). Generally, "an expert report therefore is not admissible under Rule 801......
-
Rawers v. United States
...often constitute party admissions pursuant to Fed. R. Evid. 801(d)(2)."). See also Pernix Ireland Pain Dac v. Alvogen Malta Operations Ltd., 316 F. Supp. 3d 816, 819-22 (D. Del. 2018) (Bryson, J.)(surveying case law); Lizotte v. Praxair, Inc., 640 F. Supp. 2d 1335, 1337 (W.D. Wash. 2009) (f......
-
Mountain Valley Pipeline, LLC v. 1.40 Acres of Land
...as "adoptive admissions" where the party did not call the expert to testify in the case. See Pernix Ireland Pain Dac v. Alvogen Malta Operations, Ltd., 316 F. Supp. 3d 816, 825 (D. Del. 2018) (citing McCormick on Evidence § 261 (7th ed.)). Instead, an expert's statements "will be regarded a......
-
United States v. Mims
... ... Gator ... Horizon Partners Ltd. , Civ. A. No. 13-31577, 2014 Colo ... 1995)); ... see also Pernix Ir. Pain DAC v. Alvogen Malta Operations ... ...